[ad_1]
Dunn talked about how developers use these discoveries to better inform future device enhancements, based on an understanding of how the device is adopted by clinicians and patients, as well as how it is affordable and how
Tim Dunn, PhD:
We are excited, we are presenting 7 last-minute resumes here at the conference [American Diabetes Association] and they are really developing our understanding of how the Free Freestyle system has been adopted and used, and what are some of the benefits for patients.
First of all, we did a meta-badysis of the use of Free Freestyle and the effect on [hemoglobin A1C]. Who viewed 17 studies were published, and there was a very strong conclusion that those who use Free Freestyle had, on average, a 0.5% decrease in A1C. This really supports what has been observed in different contexts. For example, we had a population of patients with type 2 diabetes, for whom this benefit was demonstrated in people under 65, which is a key finding that really supports their results.
The other big subject is obviously the cost. The development of the system has always been an important goal for Abbott in general, making the device affordable, accessible and easy to use. So, from a cost perspective, there has been an badysis of the relative cost savings, in fact, for testing at the recommended rates. For example, the ADA [recommendation of] between 6 and 10 times a day against the use of a preset with [Freestyle] Free to do this blood glucose check. This shows that this could represent savings in the range of $ 120 to $ 290 per month. This was a good statement of the value of the system
Then, an area of great importance for the use of CGM, historically, has always been the use in young adults and even in pediatrics and pediatric patients. benefits at this age, and if they adopt the system and benefit and benefit from it. There is a poster that summarizes and really examines this in two of our studies. First, the IMPACT trial, which focused on the adult population, but we focused on the under-25 subgroup, and it showed that they continued to benefit from the Improved delay and reduction of hypoglycemia. This was also shown in a second study, the SELFY study, which was for teens and also reinforced this benefit. This has been a great theme.
Finally, the last great theme was the demonstration of the use of the system in the real world. A year ago, we showed a first cut of data, about 55,000 readers, and now we show here data from 237,000 readers worldwide, from people who use the system to the House. The results show that people use a lot of the device, they scan a lot on average, they check blood sugar 13 times a day and then those who check more have more time and go for less time and hyperglycemia less time in the Hyperglycemia so it was really consistent but really good to see in this expanded dataset.
Transcription edited for clarity. 19459004 Click here to sign up for more content and updates from MD Magazine.
Related Cover >>>
Canagliflozin does not increase the risk of amputation despite the boxed warning
The role of leptin in obesity, type 2 diabetes, other metabolic conditions
Trang Ly, MBBS, FRACP, PhD: Integrative Technology in Diabetes Management
Source link
